183 related articles for article (PubMed ID: 14641553)
1. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.
Schwarz UI
Eur J Clin Invest; 2003 Nov; 33 Suppl 2():23-30. PubMed ID: 14641553
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
5. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
7. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
He SM; Zhou ZW; Li XT; Zhou SF
Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
[TBL] [Abstract][Full Text] [Related]
8. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF; Zhou ZW; Huang M
Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
[TBL] [Abstract][Full Text] [Related]
11. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
13. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
15. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
16. The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.
Wanounou M; Shaul C; Abu Ghosh Z; Alamia S; Caraco Y
Clin Pharmacol Ther; 2022 Jul; 112(1):156-163. PubMed ID: 35426132
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
18. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
